Abdolsaleh Jafari is PhD candidate in health economics at Iran University of Medical Sciences, Tehran, Iran and joined the Menzies Institute for Medical Research, University of Tasmania, Australia in July 2018 as adjunct researcher. Before starting PhD programme in Iran, Abdolsaleh worked as instructor and faculty member of department of health economics at Shiraz University of Medical Sciences in Iran for 3 years. Abdosaleh published more than 25 articles in peer review journals.


Chemotherapy for lymph node cancer is often composed of several drugs that are used in a treatment program. The aim of this study was to perform a cost-effectiveness analysis of IEV drug regimen (ifosfamide, epirubicin, and etoposide) versus ESHAP drug regimen (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) in patients with lymphoma in the south of Iran.